S&P 500   3,780.09 (-0.29%)
DOW   30,280.31 (-0.12%)
QQQ   280.79 (-0.47%)
AAPL   145.72 (-0.26%)
MSFT   247.93 (-0.38%)
META   137.63 (-1.89%)
GOOGL   100.63 (-0.99%)
AMZN   120.14 (-0.78%)
TSLA   239.38 (-4.03%)
NVDA   131.06 (-0.46%)
NIO   15.97 (-4.54%)
BABA   84.40 (+0.34%)
AMD   67.48 (-0.62%)
T   15.93 (-0.99%)
MU   54.69 (+1.35%)
CGC   3.03 (-3.50%)
F   12.46 (+0.81%)
GE   67.62 (+0.12%)
DIS   100.37 (-1.05%)
AMC   7.54 (-3.70%)
PYPL   93.99 (+1.29%)
PFE   44.03 (-0.97%)
NFLX   233.98 (-2.81%)
S&P 500   3,780.09 (-0.29%)
DOW   30,280.31 (-0.12%)
QQQ   280.79 (-0.47%)
AAPL   145.72 (-0.26%)
MSFT   247.93 (-0.38%)
META   137.63 (-1.89%)
GOOGL   100.63 (-0.99%)
AMZN   120.14 (-0.78%)
TSLA   239.38 (-4.03%)
NVDA   131.06 (-0.46%)
NIO   15.97 (-4.54%)
BABA   84.40 (+0.34%)
AMD   67.48 (-0.62%)
T   15.93 (-0.99%)
MU   54.69 (+1.35%)
CGC   3.03 (-3.50%)
F   12.46 (+0.81%)
GE   67.62 (+0.12%)
DIS   100.37 (-1.05%)
AMC   7.54 (-3.70%)
PYPL   93.99 (+1.29%)
PFE   44.03 (-0.97%)
NFLX   233.98 (-2.81%)
S&P 500   3,780.09 (-0.29%)
DOW   30,280.31 (-0.12%)
QQQ   280.79 (-0.47%)
AAPL   145.72 (-0.26%)
MSFT   247.93 (-0.38%)
META   137.63 (-1.89%)
GOOGL   100.63 (-0.99%)
AMZN   120.14 (-0.78%)
TSLA   239.38 (-4.03%)
NVDA   131.06 (-0.46%)
NIO   15.97 (-4.54%)
BABA   84.40 (+0.34%)
AMD   67.48 (-0.62%)
T   15.93 (-0.99%)
MU   54.69 (+1.35%)
CGC   3.03 (-3.50%)
F   12.46 (+0.81%)
GE   67.62 (+0.12%)
DIS   100.37 (-1.05%)
AMC   7.54 (-3.70%)
PYPL   93.99 (+1.29%)
PFE   44.03 (-0.97%)
NFLX   233.98 (-2.81%)
S&P 500   3,780.09 (-0.29%)
DOW   30,280.31 (-0.12%)
QQQ   280.79 (-0.47%)
AAPL   145.72 (-0.26%)
MSFT   247.93 (-0.38%)
META   137.63 (-1.89%)
GOOGL   100.63 (-0.99%)
AMZN   120.14 (-0.78%)
TSLA   239.38 (-4.03%)
NVDA   131.06 (-0.46%)
NIO   15.97 (-4.54%)
BABA   84.40 (+0.34%)
AMD   67.48 (-0.62%)
T   15.93 (-0.99%)
MU   54.69 (+1.35%)
CGC   3.03 (-3.50%)
F   12.46 (+0.81%)
GE   67.62 (+0.12%)
DIS   100.37 (-1.05%)
AMC   7.54 (-3.70%)
PYPL   93.99 (+1.29%)
PFE   44.03 (-0.97%)
NFLX   233.98 (-2.81%)

Vicarious Surgical Inc (NYSE:RBOT) CEO Adam David Sachs Sells 11,329 Shares

Vicarious Surgical Inc (NYSE:RBOT - Get Rating) CEO Adam David Sachs sold 11,329 shares of Vicarious Surgical stock in a transaction dated Tuesday, September 27th. The stock was sold at an average price of $3.41, for a total transaction of $38,631.89. Following the completion of the transaction, the chief executive officer now owns 1,274,175 shares of the company's stock, valued at approximately $4,344,936.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Adam David Sachs also recently made the following trade(s):

  • On Wednesday, September 21st, Adam David Sachs sold 3,683 shares of Vicarious Surgical stock. The shares were sold at an average price of $3.89, for a total transaction of $14,326.87.
  • On Monday, August 29th, Adam David Sachs sold 16,450 shares of Vicarious Surgical stock. The stock was sold at an average price of $3.83, for a total value of $63,003.50.
  • On Thursday, August 25th, Adam David Sachs sold 3,840 shares of Vicarious Surgical stock. The shares were sold at an average price of $4.13, for a total value of $15,859.20.
  • On Tuesday, August 23rd, Adam David Sachs sold 1,902 shares of Vicarious Surgical stock. The stock was sold at an average price of $3.96, for a total transaction of $7,531.92.
  • On Wednesday, July 27th, Adam David Sachs sold 11,329 shares of Vicarious Surgical stock. The shares were sold at an average price of $3.67, for a total value of $41,577.43.

Vicarious Surgical Stock Down 1.4 %


Shares of RBOT traded down $0.05 during trading hours on Thursday, hitting $3.45. The company had a trading volume of 197,582 shares, compared to its average volume of 344,754. The firm has a market cap of $419.92 million, a P/E ratio of 17.30 and a beta of 0.75. The stock's 50 day moving average price is $4.05 and its 200 day moving average price is $4.09. Vicarious Surgical Inc has a 52-week low of $2.82 and a 52-week high of $15.29.

Vicarious Surgical (NYSE:RBOT - Get Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). On average, research analysts expect that Vicarious Surgical Inc will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Wolverine Asset Management LLC increased its holdings in Vicarious Surgical by 165.7% during the 1st quarter. Wolverine Asset Management LLC now owns 10,147 shares of the company's stock valued at $51,000 after purchasing an additional 6,328 shares during the period. Rothschild Investment Corp IL increased its holdings in Vicarious Surgical by 108.0% during the 1st quarter. Rothschild Investment Corp IL now owns 111,745 shares of the company's stock valued at $566,000 after purchasing an additional 58,028 shares during the period. Northern Trust Corp purchased a new position in Vicarious Surgical during the 4th quarter valued at about $664,000. Sciencast Management LP purchased a new position in Vicarious Surgical during the 1st quarter valued at about $177,000. Finally, NewEdge Wealth LLC purchased a new position in Vicarious Surgical during the 1st quarter valued at about $141,000. Hedge funds and other institutional investors own 51.79% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, BTIG Research dropped their price target on Vicarious Surgical from $8.00 to $7.00 and set a "buy" rating for the company in a research note on Monday, July 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $11.60.

About Vicarious Surgical

(Get Rating)

Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Recommended Stories

Insider Buying and Selling by Quarter for Vicarious Surgical (NYSE:RBOT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should you invest $1,000 in Vicarious Surgical right now?

Before you consider Vicarious Surgical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vicarious Surgical wasn't on the list.

While Vicarious Surgical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.